Eptifibatide detailed information
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Eptifibatide detailed information
| |
| Systematic (IUPAC) name | |
| N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L- tryptophyl-L -prolyl-L-cysteinamide | |
| Identifiers | |
| CAS number | |
| ATC code | B01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C35H49N11O9S2 |
| Mol. mass | 831.96 g/mol |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | ~25% |
| Metabolism | ? |
| Half life | ~2.5 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Licence data |
, |
| Pregnancy cat. |
B(US) |
| Legal status |
℞ Prescription only |
| Routes | IV only |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
For patient information, click here
Overview
Eptifibatide (Integrilin®, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug that selectively blocks the platelet glycoprotein IIb/IIIa receptor. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarus barbouri). It belongs to the class of the so called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
Integrilin® is sold in two strengthes: vials containing 2 mg/ml (20 mg totally) and 0.75 mg/ml (75 mg totally).
Indications
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
The drug is always applied together with aspirin or clopidogrel and (low molecular weight heparin or unfractionated heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, lidocaine, opioid analgesics and/or benzodiazepines should be employeed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.
The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.
Contraindications and precautions
- Thrombocytopenia : The drug is contraindicated in patients with platelet counts of less than 100,000 because no clinial experience exists regarding such patients.
- Renal insufficiency : Eptifibatide undergoes renal elimination. In such patients with renal insufficiency where a glycoprotein IIb/IIIa inhibitor is likely to provide benefit, Abciximab (trade name: Reopro) is an alternative medication.
- Current bleeding tendencies or abnormally prolonged coagulation parameters observed within 30 days before starting therapy with eptifibatide is intended.
- Coagulation parameters such as Activated Clotting Time, aPTT, TT, and PT should be followed closely during therapy and afterwards.
- Allergy to eptifibatide and/or other ingredients.
- Severe, uncontrolled hypertension.
- Pregnancy : No experience exists. Pregnant patients should be treated only when clearly needed.
- Lactation : No human data exists. Breast-feeding should be avoided during treatment in order to prevent damage to the newborn.
- Geriatric patients : No differences in side effects compared with younger patients have been seen. Nevertheless, geriatric patients should be very closely observed for bleeding and other side-effects.
- Pediatric patients : Eptifibatide is not indicated in patients below 18 years of age, because no experience exists.
Side effects
It should be noticed that all patients receiving eptifibatide were seriously ill and most of them were concomitantly treated with other drugs known to have the potential to cause significant side effects. Therefore, not all side effects listed as follows may be attributable to eptifibatide treatment alone:
The major adverse event in the PURSUIT study was severe bleeding. Bleeding occurred as well at sites of clinical intervention (local sites) as at other sites (systemically) like urogenital bleedings. Sometimes, these events were severe enough to require transfusion of blood or plasma concentrates to stop bleeding and counteract anemia. Severe bleedings occurred in 4.4 and 4.7 % of patients respectively depending on the infusion rate (0.5 µg/kg and minute vs. 0.75 µg/kg and minute). A few cases of death due to severe bleeding events attributable to drug therapy were reported. No cases of hemorrhagic stroke were seen. Thrombocytopenia of unknown origin (allergic reaction?) was also noticed in 0.2 % of patients.
Additionally, hypotension was seen frequently (6 %). Cardiovascular failure was also frequent (2 %) as were serious arrhythmias (ventricular fibrillation 1.5 %, atrial fibrillation 6 %). Severe allergic (anaphylactic) reactions occurred in almost 0.2 % of patients. These reactions can be life-threatening and may be due to the peptide character of eptifibatide. Other side effects were rare and mild in nature and may not be connected to eptifibatide therapy.
Dosage regime
The recommended adult dosage is an i.v. loading dose of 180 µg/kg over 1 to 2 minutes immediately after diagnosis, followed by continuous i.v.-infusion of 2 µg/kg and minute until either hospital discharge or initiation of coronary artery bypass grafting, or for up to 72 hours. At least 4 hours before discharge all local or systemic bleedings should have been controlled and terminated.
Study results
Eptifibatide was licensed due to the positive results of the so called PURSUIT study encompassing 10,948 patients. In this study all patients had suffered either unstable angina or a non-ST-segment-elevation myocardial infarction. Significantly less patients developed a myocardial infarction under therapy with eptifibatide. Death rates showed a tendency in favour of eptifibatide, but this superiority was not statistically significant.
Additional information
Sometimes the treating physicians require the patient after discharge from hospital to continue treatment with aspirin or clopidrogel or heparin for a few weeks, some months or even for life (as usually is the case with aspirin) to prevent recurrence of symptoms, development of myocardial infarction and/or death related to cardiovascular disease. These advises should be adhered to strictly.
References
- AHFS Database Online
- Arzneimittel Datenbank (in German)
- http://www.pharmazeutische-zeitung.de/index.php?id=352&type=0 (in German)
- http://www.chemsoc.org/chembytes/ezine/1999/berressem_apr99.htm (information on the biological origin of eptifibatide)
See also
WikiDoc Research Resources for Eptifibatide detailed information | |
|---|---|
| Articles on Eptifibatide detailed information | Most recent articles on Eptifibatide detailed information • Most cited articles on Eptifibatide detailed information • Review articles on Eptifibatide detailed information • Articles on Eptifibatide detailed information in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Eptifibatide detailed information | Powerpoint slides on Eptifibatide detailed information • Images of Eptifibatide detailed information • Photos of Eptifibatide detailed information • Podcasts & MP3s on Eptifibatide detailed information • Videos on Eptifibatide detailed information |
| Evidence Based Medicine Regarding Eptifibatide detailed information | Cochrane Collaboration on Eptifibatide detailed information • Bandolier on Eptifibatide detailed information • TRIP on Eptifibatide detailed information |
| Cost Effectiveness of Eptifibatide detailed information | Cost Effectiveness of Eptifibatide detailed information |
| Clinical Trials Involving Eptifibatide detailed information | Ongoing Trials on Eptifibatide detailed information at Clinical Trials.gov • Trial results on Eptifibatide detailed information • Clinical Trials on Eptifibatide detailed information at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Eptifibatide detailed information | US National Guidelines Clearinghouse on Eptifibatide detailed information • NICE Guidance on Eptifibatide detailed information • NHS PRODIGY Guidance • FDA on Eptifibatide detailed information • CDC on Eptifibatide detailed information |
| Textbook Information on Eptifibatide detailed information | Books and Textbook Information on Eptifibatide detailed information |
| Pharmacology Resources on Eptifibatide detailed information | Dosing of Eptifibatide detailed information • Drug interactions with Eptifibatide detailed information • Side effects of Eptifibatide detailed information • Allergic reactions to Eptifibatide detailed information • Overdose information on Eptifibatide detailed information • Carcinogenicity information on Eptifibatide detailed information • Eptifibatide detailed information in pregnancy • Pharmacokinetics of Eptifibatide detailed information • |
| Genetics, Pharmacogenomics, and Proteinomics of Eptifibatide detailed information | Genetics of Eptifibatide detailed information • Pharmacogenomics of Eptifibatide detailed information • Proteomics of Eptifibatide detailed information |
| Newstories on Eptifibatide detailed information | Eptifibatide detailed information in the news • Be alerted to news on Eptifibatide detailed information • News trends on Eptifibatide detailed information |
| Commentary on Eptifibatide detailed information | Blogs on Eptifibatide detailed information |
| Patient Resources on Eptifibatide detailed information | Patient resources on Eptifibatide detailed information • Discussion groups on Eptifibatide detailed information • Patient Handouts on Eptifibatide detailed information • Directions to Hospitals Treating Eptifibatide detailed information • Risk calculators and risk factors for Eptifibatide detailed information |
| Healthcare Provider Resources on Eptifibatide detailed information | Symptoms of Eptifibatide detailed information • Causes & Risk Factors for Eptifibatide detailed information • Diagnostic studies for Eptifibatide detailed information • Treatment of Eptifibatide detailed information |
| Continuing Medical Education (CME) Programs on Eptifibatide detailed information | CME Programs on Eptifibatide detailed information |
| International Resources on Eptifibatide detailed information | Eptifibatide detailed information en Espanol • Eptifibatide detailed information en Francais |
| Business Resources on Eptifibatide detailed information | Eptifibatide detailed information in the Marketplace • Patents on Eptifibatide detailed information |
| Informatics Resources on Eptifibatide detailed information | List of terms related to Eptifibatide detailed information |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
